Enhancing ketamine translational pharmacology via receptor occupancy normalization

Neuropharmacology

Volumn 86, Issue , 2014, Pages 174-180

  Shaffer, Christopher L ^a   Osgood, Sarah M ^a   Smith, Deborah L ^a   Liu, Jianhua ^a   Trapa, Patrick E ^a  

^a PFIZER INC   (United States)

Author keywords

Cognitive disruption; Depression; Ketamine; N methyl d aspartate receptor; Receptor occupancy; Schizophrenia

Indexed keywords

DRUG METABOLITE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NORKETAMINE; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR BLOCKING AGENT; DIZOCILPINE MALEATE; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; HUMAN; IC 50; IN VIVO STUDY; MACACA FASCICULARIS; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; SINGLE DRUG DOSE; SPECIES COMPARISON; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; ANIMAL; DEPRESSION; DRUG EFFECTS; MEMORY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT; DOSE TIME EFFECT RELATION; DRUG RECEPTOR BINDING; HUMAN CELL; IC50; MATHEMATICAL COMPUTING; PLASMA CONCENTRATION-TIME CURVE; PRIMATE;

ANIMALS; DEPRESSION; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; MACACA FASCICULARIS; MALE; MEMORY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SPECIES SPECIFICITY; TRITIUM;

EID: 84905498228     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2014.07.008     Document Type: Article

References (37)

1. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, D.S. Charney, and J.H. Krystal Antidepressant effects of ketamine in depressed patients Biol. Psychiatry 47 2000 351 354 (Pubitemid 30109248)
2. S. Bjorkman, and F. Redke Clearance of fentanyl, alfentanil, methohexitone, thiopentone and ketamine in relation to estimated hepatic blood flow in several animal species: application and prediction of clearance in man J. Pharm. Pharmacol. 52 2000 1065 1074
3. V. Bubenikova-Valesova, J. Horacek, M. Vrajova, and C. Hoschl Models of schizophrenia in humans and animals based on inhibition of NMDA receptors Neurosci. Biobehav. Rev. 32 2008 1014 1023 (Pubitemid 351756510)
4. T. Chang, and A.J. Glazko Biotransformation and disposition of ketamine Int. Anesthesiol. Clin. 12 1974 157 178
5. P.G. Dayton, R.L. Stiller, D.R. Cook, and J.M. Perel The binding of ketamine to plasma proteins: emphasis on human plasma Eur. J. Clin. Pharmacol. 24 1983 825 831 (Pubitemid 13064478)
6. A.C. Doran, S.M. Osgood, J.Y. Mancuso, and C.L. Shaffer An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations Drug Metab. Dispos. 40 2012 2162 2173
7. N.R. Driesen, G. McCarthy, Z. Bhagwagar, M.H. Bloch, V.D. Calhoun, D.C. D'Souza, R. Gueorguieva, G. He, H.-C. Leung, R. Ramani, A. Anticevic, R.F. Suckow, P.T. Morgan, and J.H. Krystal The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity Neuropsychopharmacology 38 2013 2613 2622
8. R.S. Duman, and G.K. Aghajanian Synaptic dysfunction in depression: potential therapeutic targets Science 338 2012 68 72
9. B. Ebert, S. Mikkelsen, C. Thorkildsen, and F.M. Borgbjerg Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord Eur. J. Pharmacol. 333 1997 99 104 (Pubitemid 27380456)
10. F. Gastambide, S.N. Mitchell, T.W. Robbins, M.D. Tricklebank, and G. Gilmour Temporally distinct cognitive effects following acute administration of ketamine and phencyclidine in the rat Eur. J. Neuropsychopharmacol. 23 2013 1414 1422
11. M.A. Geyer, and B. Moghaddam Animal models relevant to schizophrenia disorders K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff, Neuropsychopharmacology: the 5th Generation of Progress 2002 Lippincott, Williams, & Wilkins Philadelphia 689 701
12. P. Glue, A. Gulati, M. Le Nedelec, and S. Duffull Dose- and exposure-response to ketamine in depression Biol. Psychiatry 70 2011 e9 e10
13. D.C. Goff, and J.T. Coyle The emerging role of glutamate in the pathophysiology and treatment of schizophrenia Am. J. Psychiatry 158 2001 1367 1377 (Pubitemid 32847232)
14. H. Homayoun, and B. Moghaddam NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons J. Neurosci. 27 2007 11496 11500 (Pubitemid 350006886)
15. D.C. Javitt Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions Int. Rev. Neurobiol. 78 2007 69 108
16. N. Katalinic, R. Lai, A. Somogyi, P.B. Mitchell, P. Glue, and C.K. Loo Ketamine as a new treatment for depression: a review of its efficacy and adverse events Aust. N. Z. J. Psychiatry 47 2013 710 727
17. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner, G.R. Heninger, J. Bowers, B. Malcolm, and D.S. Charney Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch. Gen. Psychiatry 51 1994 199 214 (Pubitemid 24081509)
18. J.H. Krystal, J. Perry, B. Edward, R. Gueorguieva, A. Belger, S.H. Madonick, A. Abi-Dargham, T.B. Cooper, L. MacDougall, W. Abi-Saab, and D.C. D'Souza Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function Arch. Gen. Psychiatry 62 2005 985 994
19. L.Y. Leung, and T.A. Baillie Comparitive pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6- hydroxynorketamine J. Med. Chem. 29 1986 2396 2399 (Pubitemid 17182325)
20. N. Li, B. Lee, R.-J. Liu, M. Banasr, J.M. Dwyer, M. Iwata, X.-Y. Li, G. Aghajanian, and R.S. Duman mTOR-Dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 2010 959 964
21. J.F. MacDonald, M.C. Bartlett, I. Mody, P. Pahapill, J.N. Reynolds, M.W. Salter, J.H. Schneiderman, and P.S. Pennefather Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurons J. Physiol. 432 1991 483 508
22. M. Martina, T. Comas, and G.A.R. Mealing Selective pharmacological modulation of pyramidal neurons and interneurons in the CA1 region of the rat hippocampus Front. Pharmacol. 4 2013 Article 24
23. H. Monyer, N. Burnashev, D.J. Laurie, B. Sakmann, and P.H. Seeburg Developmental and regional expression in the rat brain and functional properties of four NMDA receptors Neuron 12 1994 529 540 (Pubitemid 24100885)
24. C.J. Morgan, and H.V. Curran Acute and chronic effects of ketamine upon human memory: a review Psychopharmacology 188 2006 408 424 (Pubitemid 46758974)
25. J.W. Newcomer, N.B. Farber, V. Jevtovic-Todorovic, G. Selke, A.K. Melson, T. Hershey, S. Craft, and J.W. Olney Ketamine-induced NMDA receptor hypofunction as a model of memory impairment in psychosis Neuropsychopharmacology 20 1999 106 118 (Pubitemid 29010370)
26. J.W. Olney, and N.B. Farber Glutamate receptor dysfunction and schizophrenia Arch. Gen. Psychiatry 52 1995 998 1007
27. B.M. Roberts, D.E. Holden, C.L. Shaffer, P.A. Seymour, F.S. Menniti, C.J. Schmidt, G.V. Williams, and S.A. Castner Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction Behav. Brain Res. 212 2010 41 48
28. B.M. Roberts, C.L. Shaffer, P.A. Seymour, C.J. Schmidt, G.V. Williams, and S.A. Castner Glycine transporter inhibition reverses ketamine-induced working memory deficits NeuroReport 21 2010 390 394
29. G. Salvadore, and J.B. Singh Ketamine as a fast acting antidepressant: current knowledge and open questions CNS Neurosci. Ther. 19 2013 428 436
30. Shaffer C.L., Scialis R.J., Lotarski S., Bryce D.K., Liu J., Majchrzak M.J., Christoffersen C., Hoffmann W.E., Campbell B., Hurst R.S., McLean S., Ganong A.H., Hajos M., Seymour P.A., Menniti F.S., Schmidt C.J., Defining the mechanism-mediated exposure-response continuum of a novel AMPA receptor potentiator (Abstract). Soc. Neurosci. Abstr. 883, 17.
31. 123I]CNS-1261 in humans in vivo Nucl. Med. Biol. 33 2006 239 243
32. 123I]CNS-1261 SPET study Psychopharmacology 197 2008 401 408
33. K. Venkatakrishnan, E. Tseng, F.R. Nelson, H. Rollema, J.L. French, I.V. Kaplan, W.E. Horner, and M.A. Gibbs Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: Intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures Drug Metab. Dispos. 35 2007 1341 1349 (Pubitemid 47121775)
34. M. Wang, Y. Yang, C.-J. Wang, N.J. Gamo, L.E. Jin, J.A. Mazer, J.H. Morrison, X.-J. Wang, and A.F.T. Arnsten NMDA receptors subserve persistent neuronal firing during working memory in dorsolateral prefrontal cortex Neuron 77 2013 736 749
35. P.F. White, J. Schuttler, A. Shafer, D.R. Stanski, Y. Horaiand, and A.J. Trevor Comparative pharmacology of the ketamine isomers Br. J. Anaesth. 57 1985 197 203
36. C.A. Zarate Jr., N. Brutsche, G. Laje, D.A. Luckenbaugh, S.L. Vattem Venkata, A. Ramamoorthy, R. Moaddel, and I.W. Wainer Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression Biol. Psychiatry 72 2012 331 338
37. C.A. Zarate Jr., J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, D.A. Luckenbaugh, D.S. Charney, and H.K. Manji A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression Arch. Gen. Psychiatry 63 2006 856 864 (Pubitemid 44188478)